Skip to main content
. 2023 Jun 10;26(7):107095. doi: 10.1016/j.isci.2023.107095

Figure 8.

Figure 8

Concurrent epigenetic immunotherapy in advanced NSCLC clinical trial specimen case studies

(A, C, E, G) CD8α and CCL5 single-plex across case studies of concurrent epigenetic immunotherapy as described in the associated text, top panel baseline, bottom panel on-treatment combination epigenetic + Immunotherapy (Azacitidine + Entinostat + Nivolumab). Figure-embedded table (right) provides section H-score depicted as Baseline/On-Tx (on-treatment).

(B, D, F, H) CD8α and CCL5 multiplex IHC across case studies of concurrent epigenetic immunotherapy as described in the associated text. Top panel: baseline, bottom panel: on-treatment combination epigenetic + Immunotherapy (Azacitidine + Entinostat + Nivolumab). Figure-embedded table (right) provides section Aperio software-derived population percentages depicted as Baseline/On-Tx (on-treatment). Multiplex IHC pseudo-colored (green = CD8α, red = CCL5, and yellow = CD8α+CCL5 co-localization). All figure images are presented at 200x magnification. Representative scale bar provided in top left image of figure panel.